The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
GBA Biology and Therapies, 2019Inflammation in People with Parkinson's and a GBA Mutation and in Their Unaffected Relatives
Study Rationale:
Parkinson's is a complex disease combining genetic, environmental and inflammatory causes. Mutations in the GBA gene are a leading genetic contributor to Parkinson's disease. While... -
Biomarkers of Protein Handling/Autophagy, Exosomes and Lipid, 2019Extracellular Vesicles from Urine as Non-invasive Biomarkers
Study Rationale:
Parkinson's therapeutic development has suffered because Parkinson's symptoms develop only after significant brain degeneration has occurred, leaving significant time between disease... -
Alpha-synculein Biology and Therapies, 2018Ordering the Earliest Neuronal Response Events to Native Alpha-synuclein Exposure
Study Rationale:
The protein alpha-synuclein forms aggregates in the brains of people with Parkinson’s. Here, we will not look at the end stage of protein aggregation and cell death, which has been... -
Alpha-synculein Biology and Therapies, 2018Structure and Function of Alpha-synuclein at the Pre-synapse
Study Rationale:
Current therapeutic strategies against synucleinopathies aim to either stabilize a native form of alpha-synuclein or to reduce its levels in patients. However, the normal... -
GBA Biology and Therapies, 2018Sphingolipid and Alpha-synuclein Interactions
Study Rationale:
In Parkinson’s, a normal cellular protein called alpha-synuclein begins to fold incorrectly (misfold), and this has a central role in the development of the disease. Our research... -
Alpha-synculein Biology and Therapies, 2018Effects of Post-translational Modifications on Alpha-synuclein Aggregation
Study Rationale:
Evidence suggests that the protein alpha-synuclein can cause the death of neurons in the brains of people with Parkinson’s disease (PD) by forming clusters (or aggregates) on the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.